

Supplementary table 1. Characteristics of patients who received Atez/Bev as first-line systemic therapy (n=179)

| | Elderly patients (n=80) | Non-elderly patients (n=99) | p value |
|---|------------------------------------|--|----------------|
| Age* (years) | 81.0 (77.0–84.0) | 68.0 (62.0–71.0) | <0.001 |
| Sex (female/male) | 26/54 | 15/84 | 0.007 |
| ECOG-PS (0/1/2/3/4) | 58/17/4/1/0 | 85/9/4/0/1 | 0.061 |
| Body mass index (kg/m ²) | 23.3 (21.1–25.3) | 23.9 (21.3–26.8) | 0.146 |
| Etiology of HCC (hepatitis B/C/non-B, non-C) | 7/34/39 | 21/28/50 | 0.031 |
| Aspartate aminotransferase (IU/L) | 36 (27–57) | 36 (26–58) | 0.979 |
| Alanine aminotransferase (IU/L) | 26 (17–38) | 31 (20–43) | 0.081 |
| Albumin (g/dL)* | 3.8 (3.5–4.1) | 3.8 (3.4–4.1) | 0.810 |
| Total bilirubin (mg/dL)* | 0.7 (0.6–1.0) | 0.8 (0.6–1.1) | 0.417 |
| Platelet count (×10 ³ /m ³) * | 13.0 (10.7–17.3) | 13.0 (9.8–20.3) | 0.943 |
| Prothrombin time (%)* | 88 (83–98) | 89 (78–97) | 0.229 |
| Estimated glomerular filtration rate (mL/min/1.73 m ²)* | 58.1 (47.2–72.2) | 72.5 (59.0–83.8) | <0.001 |
| α-fetoprotein (ng/mL)* | 36.6 (7.2–542.0) | 20.0 (5.7–293.8) | 0.633 |
| Child-Pugh class (A/B/C) | 76/4/0 | 92/6/1 | 1.000 |
| BCLC stage (A/B/C/D) | 10/37/31/2 | 8/35/54/2 | 0.190 |
| Follow-up duration* (months) | 3.8 (2.0–6.7) | 5.3 (3.1–8.2) | 0.028 |
| Deaths | 7 | 9 | 1.000 |
| Causes of death (liver-related/ non–liver-related diseases) | 5/2 | 9/0 | 0.175 |

*Data are expressed as medians (interquartile range).

Atez/Bev, atezolizumab plus bevacizumab; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer.